Betson-N15 gm

Betson-N 15 gm is a topical corticosteroid-antibiotic combination indicated for the treatment of steroid-responsive inflammatory dermatoses that are infected or likely to be infected by neomycin-susceptible bacteria (e.g. Staphylococcus aureus, Proteus species, and other gram-positive and gram-negative organisms).

• Established/guideline-supported uses: Infected atopic dermatitis (eczema), infected contact dermatitis, infected discoid eczema, infected seborrhoeic dermatitis, and other infected or secondarily infected steroid-responsive dermatoses.
• Otitis externa with suspected or confirmed secondary bacterial infection and an intact tympanic membrane (drop/ointment formulations).
• Adjunct use: May be used short-term alongside appropriate systemic therapy in more extensive infected dermatoses when clinically indicated.

Betson-N 15 gm is not appropriate for primary bacterial, viral (e.g. herpes simplex, varicella), or primary fungal skin infections that are not being treated with an appropriate concurrent antimicrobial, and is not a substitute for definitive treatment of extensive or systemic infection.

Each gram of cream/ointment typically contains Betamethasone (as valerate or dipropionate) 0.05%-0.1% and Neomycin Sulphate 0.5% (equivalent to neomycin base), in a suitable cream or ointment base. Strength and exact ester of betamethasone may vary by brand; refer to the specific product label.

Betson-N 15 gm is a fixed-dose topical combination of a potent synthetic corticosteroid (betamethasone) and a broad-spectrum aminoglycoside antibiotic (neomycin sulphate). It is formulated as a cream or ointment for dermatological use, and combines anti-inflammatory, antipruritic, and antibacterial actions to treat inflamed skin conditions that are infected or at risk of secondary bacterial infection.

Betson-N 15 gm belongs to the therapeutic class of topical corticosteroids combined with topical antibiotics, used in dermatological and otological practice.

Betson-N 15 gm combines two complementary mechanisms of action:

• Betamethasone is a synthetic, potent glucocorticoid that binds intracellular glucocorticoid receptors, inducing anti-inflammatory proteins (e.g. lipocortin) and suppressing pro-inflammatory mediators (prostaglandins, leukotrienes, cytokines). This reduces vasodilation, oedema, itching, and inflammatory cell infiltration in the skin.
• Neomycin sulphate is an aminoglycoside antibiotic that binds the bacterial 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis, producing a bactericidal effect against many gram-positive and gram-negative organisms commonly found in secondarily infected skin lesions.

Topical absorption of both components is normally low through intact skin, but increases significantly with application to broken or denuded skin, use under occlusion, application over large body surface areas, or in infants and young children, raising the risk of systemic corticosteroid and aminoglycoside effects.

For external/topical use only. Clean and dry the affected area before application (unless otherwise directed). Apply a thin film and gently massage in. Avoid contact with the eyes, mouth, and mucous membranes. Do not apply to broken skin, wounds, or ulcers unless specifically directed by a physician, and do not cover with airtight (occlusive) dressings unless instructed.

Betson-N 15 gm has few clinically significant interactions when used topically as directed, because systemic absorption is normally minimal. However:

• Concurrent systemic aminoglycosides: Concomitant use with other aminoglycoside antibiotics (systemic or topical on other body sites) or with other ototoxic/nephrotoxic drugs may increase the risk of cumulative ototoxicity or nephrotoxicity if significant absorption of neomycin occurs (e.g. with prolonged use over large or denuded areas).
• Neuromuscular blocking agents: Neomycin can potentiate and prolong the effects of neuromuscular blocking agents if absorbed systemically in significant amounts, which is a concern mainly in the perioperative setting with extensive application.
• Potent CYP3A4 inhibitors (e.g. ritonavir, itraconazole): May theoretically increase systemic corticosteroid exposure if significant absorption occurs, particularly with prolonged or extensive use.

These interactions are of greatest concern when Betson-N 15 gm is applied over large areas, under occlusion, or on broken skin for prolonged periods; inform your physician about all other medicines you are using.

When used as directed for short periods on limited skin areas, Betson-N 15 gm is generally well tolerated. Reported adverse effects include:

• Common/local: Burning, stinging, itching, dryness, or irritation at the application site.
• Allergic contact sensitization: Allergic contact dermatitis to neomycin (or, less commonly, to betamethasone) can occur, presenting as worsening redness, itching, or rash; this may be mistaken for the condition being treated. Discontinue use and seek medical advice if the treated area worsens or a new rash develops.
• With prolonged/extensive use: Skin thinning (atrophy), striae (stretch marks), telangiectasia (visible blood vessels), perioral dermatitis, acneiform eruptions, hypopigmentation, hypertrichosis, and delayed wound healing.
• Systemic effects (rare, associated with prolonged/extensive/occluded use, especially in children): Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushingoid features, and, with significant neomycin absorption, ototoxicity (hearing loss, tinnitus, vertigo) or nephrotoxicity.

Pregnancy: There is limited controlled data on topical Betson-N 15 gm use in human pregnancy. Topical corticosteroids have been associated with fetal growth restriction in some studies when used extensively, and neomycin crosses the placenta. Betson-N 15 gm should be used in pregnancy only if clearly needed and the potential benefit justifies the potential risk to the fetus; use the smallest effective amount for the shortest duration and consult a physician before use.

Lactation: It is not known whether topically applied betamethasone or neomycin are excreted in clinically significant amounts in breast milk. Caution is advised; avoid application to the breast/nipple area before breastfeeding, and consult a physician before use while breastfeeding.

Observe the following precautions when using Betson-N 15 gm:

• Duration and extent of use: Avoid prolonged, continuous, or extensive use, particularly over large body surface areas, on broken/denuded skin, or under occlusive dressings, as this increases systemic absorption of both components and the risk of HPA-axis suppression and neomycin-related toxicity. This risk is greater in infants and young children due to their larger skin-surface-to-body-weight ratio.
• Contact sensitization: Long-term or repeated use increases the risk of allergic contact sensitization to neomycin. Stop treatment and consult a physician if the treated area worsens, becomes more inflamed, or a new rash appears.
• Skin thinning: Avoid prolonged use on the face, groin, axillae, and other skin folds, which are more susceptible to steroid-induced atrophy and striae.
• Masking of infection: The anti-inflammatory action of betamethasone may mask signs of worsening or spreading infection; monitor the treated area and seek medical review if it does not improve or worsens.
• Eye contact: Avoid contact with the eyes; do not use for ocular conditions unless a specific ophthalmic formulation and physician instruction indicate otherwise. Prolonged periocular use may increase the risk of glaucoma and cataract.
• Not for untreated infections: Do not use on primary viral, fungal, or untreated bacterial skin infections (see Contraindications).
• Antimicrobial stewardship: Take exactly as prescribed by your physician; do not stop, extend, skip doses, or share this medicine with others without medical advice, to reduce the risk of antibiotic resistance and adverse effects.

Topical overdose or misuse (excessive quantity, prolonged duration, or use over large/occluded areas) of Betson-N 15 gm can lead to systemic corticosteroid effects (e.g. Cushingoid features, HPA-axis suppression) and, rarely, neomycin-related ototoxicity or nephrotoxicity. If accidental ingestion occurs or excessive/prolonged application is suspected, discontinue use and seek immediate medical attention or contact a poison control center/emergency services; do not attempt specific home treatment. A physician may advise gradual tapering of corticosteroid use and monitoring of hearing and renal function if significant systemic absorption is suspected.

Store at room temperature (below 30°C), away from light and moisture. Do not freeze. Keep the container tightly closed and out of the reach of children.

Children: Betson-N 15 gm should be used with caution in children, at the lowest effective strength/amount and for the shortest duration necessary, under medical supervision, due to a greater risk of HPA-axis suppression and neomycin absorption from a proportionally larger skin-surface-to-body-weight ratio. Use in infants (particularly under 1-2 years of age) is generally not recommended unless specifically directed by a physician; avoid use with occlusive dressings (including tight-fitting diapers/nappies acting as occlusion) in this age group.

Elderly: Use the minimum effective quantity for the shortest duration, as elderly patients may have thinner skin that is more susceptible to atrophy and increased absorption.

Renal impairment: Use with caution; reduced renal clearance of any absorbed neomycin may increase the risk of accumulation and nephrotoxicity/ototoxicity with extensive or prolonged use.

Hepatic impairment: No specific dosage adjustment is established for topical use; use as directed by a physician.

Treatment with Betson-N 15 gm should generally be limited to short courses (commonly up to 7 days, or as directed by the prescribing physician) and re-evaluated if there is no improvement. Prolonged, uninterrupted use beyond the recommended duration should be avoided due to the increased risk of skin atrophy, HPA-axis suppression, and contact sensitization.

Topical corticosteroid (betamethasone) combined with a topical aminoglycoside antibiotic (neomycin sulphate).

Betamethasone suppresses inflammation by binding glucocorticoid receptors and downregulating inflammatory mediators, reducing redness, swelling, and itching. Neomycin sulphate acts as a bactericidal antibiotic by binding the bacterial 30S ribosomal subunit and disrupting protein synthesis, eliminating susceptible bacteria contributing to secondary skin infection.

Betson-N 15 gm may be used in children only under close medical supervision. Safety and efficacy for prolonged or unsupervised use in infants and young children have not been established, and use in infants below 1-2 years of age is generally not recommended except on specific physician advice. Because children have a larger skin-surface-area-to-body-weight ratio, they are at greater risk of systemic corticosteroid absorption (HPA-axis suppression, growth effects with long-term use) and of neomycin-related toxicity. The lowest effective strength, smallest amount, and shortest duration should be used, and occlusive dressings (including tight diapers) should be avoided.